| MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy GW Sledge Jr, M Toi, P Neven, J Sohn, K Inoue, X Pivot, O Burdaeva, ... Journal of clinical oncology 35 (25), 2875-2884, 2017 | 1476 | 2017 |
| MONARCH 3: abemaciclib as initial therapy for advanced breast cancer MP Goetz, M Toi, M Campone, J Sohn, S Paluch-Shimon, J Huober, ... Journal of Clinical Oncology 35 (32), 3638-3646, 2017 | 1461 | 2017 |
| The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: a … GW Sledge, M Toi, P Neven, J Sohn, K Inoue, X Pivot, O Burdaeva, ... JAMA oncology 6 (1), 116-124, 2020 | 789 | 2020 |
| Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non–small cell lung cancer, and other solid tumors A Patnaik, LS Rosen, SM Tolaney, AW Tolcher, JW Goldman, L Gandhi, ... Cancer discovery 6 (7), 740-753, 2016 | 663 | 2016 |
| MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer MN Dickler, SM Tolaney, HS Rugo, J Cortés, V Diéras, D Patt, H Wildiers, ... Clinical Cancer Research 23 (17), 5218-5224, 2017 | 633 | 2017 |
| Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE) SRD Johnston, N Harbeck, R Hegg, M Toi, M Martin, ZM Shao, QY Zhang, ... Journal of Clinical Oncology 38 (34), 3987-3998, 2020 | 604 | 2020 |
| MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer S Johnston, M Martin, A Di Leo, SA Im, A Awada, T Forrester, M Frenzel, ... NPJ breast cancer 5 (1), 5, 2019 | 460 | 2019 |
| Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov. 2016; 6 … A Patnaik, LS Rosen, SM Tolaney, AW Tolcher, JW Goldman, L Gandhi, ... DOI: https://doi. org/10.1158/2159-8290. CD-16-0095, 740-753, 0 | 135 | |
| A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer S Pant, SF Jones, CD Kurkjian, JR Infante, KN Moore, HA Burris, ... European journal of cancer 56, 1-9, 2016 | 93 | 2016 |
| MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2-breast cancer, after chemotherapy for advanced disease. MN Dickler, SM Tolaney, HS Rugo, J Cortes, V Diéras, DA Patt, H Wildiers, ... Journal of Clinical Oncology 34 (15_suppl), 510-510, 2016 | 88 | 2016 |
| monarchE Committee Members and Investigators. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast … SRD Johnston, N Harbeck, R Hegg, M Toi, M Martin, ZM Shao, QY Zhang, ... J Clin Oncol 38 (34), 3987-3998, 2020 | 79 | 2020 |
| Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy A Di Leo, J O’Shaughnessy, GW Sledge Jr, M Martin, Y Lin, M Frenzel, ... NPJ Breast Cancer 4 (1), 41, 2018 | 57 | 2018 |
| LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer. A Patnaik, LS Rosen, SM Tolaney, AW Tolcher, JW Goldman, L Gandhi, ... Journal of Clinical Oncology 32 (15_suppl), 534-534, 2014 | 49 | 2014 |
| Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer A Patnaik, LS Rosen, SM Tolaney, AW Tolcher, JW Goldman, L Gandhi, ... CANCER RESEARCH 74 (19), 2014 | 48 | 2014 |
| MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2-advanced breast cancer A Di Leo, M Toi, M Campone, J Sohn, S Paluch-Shimon, J Huober, ... Annals of Oncology 28, v609, 2017 | 32 | 2017 |
| Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer. JW Goldman, L Gandhi, A Patnaik, LS Rosen, JF Hilton, ... Journal of Clinical Oncology 32 (15_suppl), 8026-8026, 2014 | 31 | 2014 |
| MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2-advanced breast cancer GW Sledge, M Toi, P Neven, J Sohn, K Inoue, X Pivot, O Burdaeva, ... Annals of Oncology 30, v856, 2019 | 30 | 2019 |
| MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2-advanced breast cancer who progressed on endocrine therapy GW Sledge, M Toi, P Neven, J Sohn, K Inoue, XB Pivot, ON Burdaeva, ... Journal of Clinical Oncology 35 (15_suppl), 1000-1000, 2017 | 20 | 2017 |
| A concise and efficient approach to 2, 6-disubstituted 4-fluoropyrimidines from α-CF3 aryl ketones F Liu, X Zhang, Q Qian, C Yang Synthesis 52 (02), 273-280, 2020 | 18 | 2020 |
| MONARCH 3: A randomized phase III study of anastrozole or letrozole plus abemaciclib, a CDK4/6 inhibitor, or placebo in first-line treatment of women with HR+, HER2 … MP Goetz, M Toi, S Klise, M Frenzel, N Bourayou, A Di Leo Journal of Clinical Oncology 33 (15_suppl), TPS624-TPS624, 2015 | 17 | 2015 |
